Evidence map›Paper›PMID 42394854›Full record

ArticleDiscover pharmaceutical sciences2026

Concomitant activation of D

Luke Bransom, Ava P Bassett, Mi Zhou, Richard B Mailman, Yang Yang

Abstract read
In one paragraph

Article in Discover pharmaceutical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Luke BransomDepartment of Neuroscience and Experimental Therapeutics, Penn State University College of Medicine, 500 University Dr. MC R130, Hershey, PA 17033 USA.
Ava P BassettDepartment of Neuroscience and Experimental Therapeutics, Penn State University College of Medicine, 500 University Dr. MC R130, Hershey, PA 17033 USA.
Mi ZhouDepartment of Neurology, Penn State Milton S. Hershey Medical Center, Hershey, PA 17033 USA.
Richard B MailmanDepartment of Neuroscience and Experimental Therapeutics, Penn State University College of Medicine, 500 University Dr. MC R130, Hershey, PA 17033 USA.
Yang YangDepartment of Neuroscience and Experimental Therapeutics, Penn State University College of Medicine, 500 University Dr. MC R130, Hershey, PA 17033 USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rationale: Methylphenidate is commonly prescribed to manage symptoms of attention-deficit/hyperactivity disorder (ADHD), but like other stimulants it has variable effectiveness. Methylphenidate works by increasing the synaptic availability of dopamine and norepinephrine, resulting in stimulation of dopaminergic and adrenergic receptors. One hypothesis is that selective receptor targeting may be more effective clinically and have fewer side effects than non-selective stimulants. Objectives and methods: To test this hypothesis, we compared methylphenidate with three compounds: the selective D Results: Co-administration of an α Conclusions: These findings suggest that potential benefits may emerge from the coadministration of selective agents (e.g., α

Indexed as

Cognitive flexibilityD1 dopaminergic receptor agonistMethylphenidateWorking memoryα2 adrenergic receptor agonist

Identifiers

PMID42394854
PMCPMC13326939

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.